Cognition in Parkinson's Disease
- 1st Edition, Volume 269 - February 18, 2022
- Editors: Nandakumar Narayanan, Roger Albin
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 0 1 6 4 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 1 6 5 - 9
Cognition in Parkinson's Disease, Volume 269 in the Progress in Brain Research series, highlights new advances in the field, with this new volume presenting interesting c… Read more
Purchase options
Cognition in Parkinson's Disease, Volume 269 in the Progress in Brain Research series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Cognition in Prodromal Parkinson’s disease, The epidemiology of cognitive function in Parkinson's disease, Real-life consequences of cognitive dysfunction in Parkinson’s disease, Animal models of cognition in Parkinson’s disease, Functional neuroanatomy of cognition in Parkinson’s disease, Neuroimaging approaches to cognition in Parkinson’s disease, Cognitive dysfunction and neuropsychiatric aspects of Parkinson’s disease, Neuropsychology of Parkinson’s disease, Cholinergic Systems, Attentional-Motor Integration, and Cognitive Control in Parkinson Disease, and much more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in Progress in Brain Research series
- Updated release includes the latest information on Cognition in Parkinson's Disease
Undergraduates, graduates, academics, and researchers in the field of neurology and brain research
Defining the problem
1. Introduction
N. S. Narayanan and Roger L. Albin
2. The epidemiology of cognitive function in Parkinson's disease
Caroline M Tanner and Meredith A. Bock
3. Neuropsychology of Parkinson’s disease
Steven Anderson and Cole Toovey
4. Cognitive dysfunction and neuropsychiatric aspects of Parkinson’s
disease
Laura Marsh and Gabriela Austgen
Clinical characteristics
5. Cognition in Prodromal Parkinson’s disease
Inga Liepelt-Scarfone, Anja Ophey and Elke Kalbe
6. Real-life consequences of cognitive dysfunction in Parkinson’s disease
Ergun Y. Uc and Kevin Kay
7. Cognitive control and Parkinson’s disease
James F. Cavanagh, Sarah Pirio Richardson and Sephira Ryman
8. Speech dysfunction, cognition, and Parkinson’s disease
Jeremy Greenlee, Kris Tjaden, Andrea Rohl, Stephanie Gutierrez and Angela C. Roberts
Pathophysiology
9. Neuropathology and Cognition in Parkinson’s disease
David J. Irwin and David Coughlin
10. Genetics of cognitive dysfunction in Parkinson’s disease
Roy Alcalay and Adina Wise
11. Animal models of action control and cognitive dysfunction in Parkinson’s disease
Bernard Balleine
12. Neuroimaging approaches to cognition in Parkinson’s disease
Kathleen L. Poston, Leila Montaser-Kouhsari and Christina Young
Circuit mechanisms
13. Functional neuroanatomy of cognition in Parkinson’s disease
Nader Pouratian, Timothy J. Florence, Cody Wolfe and Koorosh Mirpour
14. Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease'
Roshan Cools, Jorryt Tichelaar, Rick Helmich, Bas Bloem, Rianne Esselink, Katrijn Smulders and Monique Timmer
15. Cholinergic Systems, Attentional-Motor Integration, and Cognitive Control in Parkinson Disease
Roger L. Albin, Martin Sarter, Sygrid van der Zee, Teus van Laar, Cindy Lustig, Martijn Muller and Nicolaas I.L.J Bohnen
16. Cognition and serotonin in Parkinson’s disease
Philippe Huot, Sebastien Belliveau, Imane Frouni and Cynthia Kwan
Towards therapies
17. Caring for patients with cognitive dysfunction, fluctuations and dementia caused by Parkinson’s Disease
Georgina Aldridge, Oday Halhouli and Qiang Zhang
18. Neuromodulation of cognition in Parkinson’s disease
N. S. Narayanan, Rachel Cole, Derrick Okine and Brooke Yeager
19. The way forward for cognition and Parkinson's disease
N. S. Narayanan and Roger L. Albin
- Edition: 1
- Volume: 269
- Published: February 18, 2022
- Language: English
NN
Nandakumar Narayanan
Dr. Nandakumar Narayanan is Associate Professor & Associate Director of the Iowa Neuroscience Institute, University of Iowa. The specific problem of his research is cognitive dysfunction in Parkinsons disease. His current research focuses on the influence of dopamine on prefrontal networks controlling cognitive behaviors such as timing and performance monitoring. His research combines ensemble recording from populations of neurons in awake, behaving animals with specific manipulations using techniques such as optogenetic stimulation, targeted pharmacology, or selective genetic disruption with RNA interference. HIs research hopes to identify new treatment strategies that can be translated to a clinical setting.
Affiliations and expertise
Associate Professor of Neurology, Department of Neurology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, USARA
Roger Albin
Roger L. Albin, MD, is a professor of neurology and co-director of the Movement Disorders Clinic in the Department of Neurology in the University of Michigan Medical School. In addition, he serves as chief of neuroscience research at the VA Ann Arbor Healthcare System Geriatric Research Education and Clinical Center.
Dr. Albin joined the University of Michigan faculty in 1988 as an instructor in the Department of Neurology. He was promoted to assistant professor in 1989; associate professor in 1994; and achieved his current rank of full professor in 2000.
After completing his undergraduate degree at Oberlin College in Ohio, Dr. Albin earned his medical degree from the University of Pittsburgh School of Medicine in 1982, and completed his residency at the University of Michigan in 1986. He also completed a movement disorders fellowship in 1988 under Drs. Anne Young and John Penney.
His clinical and research interests include the underlying neurobiologic causes of the clinical features of movement disorders, basal ganglia structure and function, Parkinson's disease, Tourette syndrome, dementias, dystonias and Huntington's disease. His laboratory is pursuing work on basic mechanisms of neurodegeneration in Huntington disease using mouse genetic models. Dr. Albin also has participated in neuroprotective clinical trials for both Huntington's disease and Parkinson's disease.
The present focus of Dr. Albin's group is uncovering the basis for non-motor (sleep disorders, depression, dementia, autonomic dysfunction) problems in Parkinson's disease. He is very interested in applying positron emission tomography (PET) imaging methods to improve diagnosis of dementing disorders like Alzheimer's disease. The hope is that understanding how specific brain alterations cause specific clinical features will lead to improved treatments.
Dr. Albin currently serves as a site investigator for the National Institutes of Health (NIH) Exploratory Trials in Parkinson disease (NET-PD) initiative. His work is supported by grants from the NIH, the Michael J. Fox Foundation and the High Q Foundation.
A member of the American Academy of Neurology, the American Association for the Advancement of Science, the American Neurologic Association, and the Society for Neuroscience, Dr. Albin currently serves on the editorial boards of Experimental Neurology, Neurology and Neurobiology of Disease.
Affiliations and expertise
Professor of Neurology, Neuroscience Graduate Program, University of MIchigan, USARead Cognition in Parkinson's Disease on ScienceDirect